American Heart Journal
Volume 157, Issue 2 , Pages 352-360.e2 , February 2009

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

  • Daniel Bloomfield, MD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • Corresponding Author InformationReprint requests: Daniel Bloomfield, MD, Merck Research Laboratories, 126 East Lincoln Avenue, RY34-A218, Rahway, NJ 07065-0900.
    • ,
  • Gary L. Carlson, BS

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Aditi Sapre, PhD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Diane Tribble, PhD

      Affiliations

    • Isis Pharmaceuticals, Carlsbad, CA
    • ,
  • James M. McKenney, Pharm D

      Affiliations

    • Virginia Commonwealth University and National Clinical Research, Inc, Richmond, VA
    • ,
  • Thomas W. Littlejohn III, MD

      Affiliations

    • Piedmont Medical Research, Winston-Salem, NC
    • ,
  • Christine McCrary Sisk, BS

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Yale Mitchel, MD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Richard C. Pasternak, MD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ

Received 9 June 2008 ,Accepted 26 September 2008.

References 

  1. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255–1274
  2. Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis. 1985;58:175–186
  3. Thompson A, Di Angelantonio E, Sarwar N, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777–2788
  4. Barter PJ, Brewer HB, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160–167
  5. Davidson MH, McKenney JM, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774–1781
  6. McKenney JM, Davidson MH, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782–1790
  7. Barter PJ, Caulfield M, Eriksson M, et al. for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122
  8. Kastelein JJ, van Leuven SI, Burgess L, et al. for the RADIANCE 1 Investigators Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620–1630
  9. Nissen SE, Tardif JC, Nicholls SJ, et al. for the ILLUSTRATE Investigators Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304–1316
  10. Bots ML, Visseren FL, Evans GW, et al. for the RADIANCE 2 Investigators Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153–160
  11. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370:1907–1914
  12. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159–2165
  13. Fridewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterols in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  14. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45:2136–2141
  15. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary artery disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082–1085
  16. Ariyo AA, Thach C, Tracy R, et al. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108–2115
  17. Ridker PM, Cannon CP, Morrow D, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;325:20–28
  18. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008;154:1465–1473
  19. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–1255
  20. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–381
  21. Matsuura F, Wang N, Chen W, et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 2006;116:1435–1442
  22. Sugano M, Makino N, Sawada S, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998;273:5033–5036
  23. Rittershaus CW, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2106–2112
  24. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000;406:203–207
  25. Morehouse , Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res. 2007;48:1263–1272

 Registered Clinical Trial No.: NCT00325455.

PII: S0002-8703(08)00828-4

doi: 10.1016/j.ahj.2008.09.022

American Heart Journal
Volume 157, Issue 2 , Pages 352-360.e2 , February 2009

Article Tools

* Image Usage & Resolution